8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following: | | | | | | | | | June 30, | | December 31, | | | 2026 | | 2025 | Professional services | | $ | — | | $ | 800 | Development costs | | | 183 | | | 269 | Accrued revenue reserves (1) | | | 155 | | | 155 | Compensation and benefits | | | 17 | | | 180 | Other | | | 41 | | | 104 | Accrued expenses and other current liabilities | | $ | 396 | | $ | 1,508 |
| (1) | These amounts represent estimated provisions for product returns, rebates and discounts, prior to the sale of the rights to manufacture, sell, distribute, market and commercialize EYSUVIS and INVELTYS and to develop, manufacture, market and otherwise exploit AMPPLIFY Drug Delivery Technology (the “Commercial Business”) to Alcon.. Estimated provisions were deducted from gross revenues at the time revenues were recognized and are included in accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets. These provisions reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the contract. |
|